In conclusion, the treatment of Roflumilast is able to re-activate cAMP/PKA/CREB signaling axis in ovarian cancer, leading to FtMt-mediated tumor inhibition in vitro and vivo. Therefore, the application of PDE inhibitors for cancer merits consideration in clinical. The gene discussed is CREB1; the disease is cancer.